1
|
Dergilev KV, Makarevich PI, Tsokolaeva ZI, Boldyreva MA, Beloglazova IB, Zubkova ES, Menshikov MY, Parfyonova YV. Comparison of cardiac stem cell sheets detached by Versene solution and from thermoresponsive dishes reveals similar properties of constructs. Tissue Cell 2016; 49:64-71. [PMID: 28041835 DOI: 10.1016/j.tice.2016.12.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2016] [Revised: 11/13/2016] [Accepted: 12/03/2016] [Indexed: 01/04/2023]
Abstract
Cell sheets (CS) from c-kit+ cardiac stem cell (CSC) hold a potential for application in regenerative medicine. However, manufacture of CS may require thermoresponsive dishes, which increases cost and puts one in dependence on specific materials. Alternative approaches were established recently and we conducted a short study to compare approaches for detachment of CS from c-kit+ CSC. Our in-house developed method using chelation by Versene solution was compared to UpCell™ thermoresponsive plates in terms of CSC proliferation, viability, gap junction formation and engraftment in a model of myocardial infarction. Use of Versene solution instead of thermoresponsive dishes resulted in comparable CS thickness (approximately 100mcm), cell proliferation rate and no signs of apoptosis detected in both types of constructs. However, we observed a minor reduction of gap junction count in Versene-treated CS. At day 30 after delivery to infarcted myocardium both types of CS retained at the site of transplantation and contained comparable amounts of proliferating cells indicating engraftment. Thus, we may conclude that detachment of CS from c-kit+ CSC using Versene solution followed by mechanical treatment is an alternative to thermoresponsive plates allowing use of routinely available materials to generate constructs for cardiac repair.
Collapse
Affiliation(s)
- Konstantin V Dergilev
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation
| | - Pavel I Makarevich
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation; Lomonosov Moscow State University, Medical Research and Education Centre, Institute of Regenerative Medicine, Laboratory of gene and cell therapy, 119192, Moscow, Russian Federation.
| | - Zoya I Tsokolaeva
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation
| | - Maria A Boldyreva
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation
| | - Irina B Beloglazova
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation
| | - Ekaterina S Zubkova
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation
| | - Mikhail Yu Menshikov
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation
| | - Yelena V Parfyonova
- Russian Cardiology Research and Production Complex, Laboratory of Angiogenesis, 121552, Moscow, Russian Federation; Lomonosov Moscow State University, Faculty of Medicine, Laboratory of gene and cell technologies, 119192, Moscow, Russian Federation
| |
Collapse
|
2
|
Iyngkaran P, Thomas M. Bedside-to-Bench Translational Research for Chronic Heart Failure: Creating an Agenda for Clients Who Do Not Meet Trial Enrollment Criteria. CLINICAL MEDICINE INSIGHTS-CARDIOLOGY 2015; 9:121-32. [PMID: 26309418 PMCID: PMC4527366 DOI: 10.4137/cmc.s18737] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2015] [Revised: 03/09/2015] [Accepted: 03/25/2015] [Indexed: 01/09/2023]
Abstract
Congestive heart failure (CHF) is a chronic condition usually without cure. Significant developments, particularly those addressing pathophysiology, mainly started at the bench. This approach has seen many clinical observations initially explored at the bench, subsequently being trialed at the bedside, and eventually translated into clinical practice. This evidence, however, has several limitations, importantly the generalizability or external validity. We now acknowledge that clinical management of CHF is more complicated than merely translating bench-to-bedside evidence in a linear fashion. This review aims to help explore this evolving area from an Australian perspective. We describe the continuation of research once core evidence is established and describe how clinician-scientist collaboration with a bedside-to-bench view can help enhance evidence translation and generalizability. We describe why an extension of the available evidence or generating new evidence is occasionally needed to address the increasingly diverse cohort of patients. Finally, we explore some of the tools used by basic scientists and clinicians to develop evidence and describe the ones we feel may be most beneficial.
Collapse
Affiliation(s)
- P Iyngkaran
- Flinders University, NT Medical School, Darwin, Australia
| | - M Thomas
- Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia
| |
Collapse
|
3
|
Recent advances of stem cell therapy for retinitis pigmentosa. Int J Mol Sci 2014; 15:14456-74. [PMID: 25141102 PMCID: PMC4159862 DOI: 10.3390/ijms150814456] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2014] [Revised: 07/24/2014] [Accepted: 08/11/2014] [Indexed: 12/22/2022] Open
Abstract
Retinitis pigmentosa (RP) is a group of inherited retinal disorders characterized by progressive loss of photoreceptors and eventually leads to retina degeneration and atrophy. Until now, the exact pathogenesis and etiology of this disease has not been clear, and many approaches for RP therapies have been carried out in animals and in clinical trials. In recent years, stem cell transplantation-based attempts made some progress, especially the transplantation of bone marrow-derived mesenchymal stem cells (BMSCs). This review will provide an overview of stem cell-based treatment of RP and its main problems, to provide evidence for the safety and feasibility for further clinical treatment.
Collapse
|